What You Should Know:
– ArteraAI, a leader in artificial intelligence (AI)-powered cancer tests, today announced a significant achievement – the inclusion of their ArteraAI Prostate Test in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer.
– This marks a major milestone for ArteraAI, solidifying its position at the forefront of AI-driven oncology and personalized patient care.
A First for AI-powered Testing
The ArteraAI Prostate Test is the first and only AI-enabled predictive and prognostic test recommended in the NCCN Guidelines for localized prostate cancer. The NCCN Guidelines classify the ArteraAI Prostate Test with Level IB evidence, signifying the highest level of supporting evidence based on rigorous validation. This validation involved multiple randomized, phase 3 clinical trials, demonstrating the test’s robustness and reliability. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
“We are immensely proud of ArteraAI as the inaugural AI company to earn recognition within national guidelines,” said Andre Esteva, CEO and Co-Founder of ArteraAI. “This significant milestone not only celebrates ArteraAI’s success but also paves the way for the integration of AI-enabled solutions into clinical practice, illustrating their potential to enhance personalized patient care.”
